MOH — authorised 16 October 2007
- Marketing authorisation holder: BRISTOL MYERS SQUIBB
- Status: likely_approved
MOH authorised Ixempra Kit on 16 October 2007
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 16 October 2007.
BRISTOL MYERS SQUIBB holds the Israeli marketing authorisation.